Gsa Capital Partners LLP Cellectar Biosciences, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$8.2 - $12.4 $2.44 Million - $3.69 Million
-297,653 Closed
0 $0
Q2 2021

Aug 05, 2021
BUY
$11.8 - $18.2 $1.66 Million - $2.57 Million
140,957 Added 89.96%
297,653 $354,000
Q1 2021

May 10, 2021
BUY
$15.2 - $25.0 $2.38 Million - $3.92 Million
156,696 New
156,696 $252,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $9.17M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email